Press release
Endometrial Cancer Pipeline Grows as 50+ Pharma Companies Advance Novel Gynecologic Cancer Therapies, Finds DelveInsight | Selinexor, Abemaciclib, NP137, CT-0508
Endometrial Cancer - Pipeline Insight, 2026
DelveInsight's "Endometrial Cancer - Pipeline Insight, 2026" report provides comprehensive insights about 50+ companies developing over 55 pipeline drugs in the endometrial cancer landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.
Explore the latest breakthroughs in the Endometrial Cancer treatment landscape. Learn more about the evolving endometrial cancer pipeline today @ https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr
Key Takeaways from the Endometrial Cancer Pipeline Report
*
In March 2026, letrozole monotherapy failed to demonstrate noninferiority to chemotherapy followed by letrozole in patients with stage II-IV low-grade serous ovarian carcinoma at the SGO Annual Meeting.
*
In February 2026, the SISTER trial reported that one-on-one peer support significantly increased treatment completion rates to 84% for Black women with high-risk endometrial cancer compared to 50% for those without support.
*
In September 2025, the FDA hosted "Endometrial Cancer - Rising incidence. Rising innovation," highlighting that 2025 estimates include over 69,000 new cases and nearly 14,000 deaths in the U.S..
*
Interim Phase 1 data for mocertatug rezetecan showed rapid and deep responses in patients with recurrent or advanced endometrial cancer, with a confirmed ORR of 67% at a 4.8 mg/kg dose.
*
Endometrial cancer is the most common gynecologic malignancy in developed countries, with incidence rising due to factors such as aging and obesity.
*
The current pipeline features more than 55 drugs being advanced by over 50 global companies across all clinical stages.
*
Selinexor, an oral exportin 1 inhibitor, is one of the most advanced pipeline candidates, currently in Phase III clinical trials for advanced or recurrent cases.
*
Incyte Corporation is among the key players with advanced-stage drug candidates in Phase II clinical evaluation.
Download for updates and the latest revolution in Endometrial Cancer care @ Endometrial Cancer Market Insight, Epidemiology And Market Forecast [https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Endometrial Cancer Emerging Drugs Profile
Selinexor: Karyopharm Therapeutics
Selinexor is an oral selective inhibitor of nuclear export (SINE) compound that binds to and inhibits the nuclear export protein XPO1. It is currently being evaluated in Phase III clinical trials for the treatment of advanced or recurrent endometrial cancer. By blocking the export of tumor suppressor proteins from the nucleus, selinexor aims to restore normal cellular growth control mechanisms in cancer cells.
Abemaciclib: Eli Lilly and Company
Abemaciclib is an oral inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). It is showing clinical benefit in Phase II trials for endometrial cancer, particularly when used in combination with hormonal therapies. The therapy targets the cell cycle to prevent tumor cell proliferation and is being explored as a potential new treatment option for advanced stages of the disease.
NP137: Netris Pharma
NP137 is a first-in-class monoclonal antibody designed to target netrin-1, a protein often overexpressed in various cancers, including endometrial cancer. By blocking the interaction between netrin-1 and its receptors, NP137 aims to induce apoptosis in tumor cells. It is currently undergoing clinical assessment to determine its efficacy and safety in patients with gynecologic malignancies.
For more information on the Endometrial Cancer Emerging Drugs Profile, download DelveInsight's comprehensive Endometrial Cancer Pipeline Insight report [https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The Endometrial Cancer Pipeline Report Provides
*
Detailed insights about more than 50 companies developing therapies for Endometrial Cancer, including aggregate therapies developed by each.
*
A comprehensive overview of different therapeutic candidates segmented into early-stage, mid-stage, and late-stage development.
*
Analysis of companies involved in targeted therapeutics development, including active and inactive projects.
*
Drug profiles based on route of administration, target receptor, monotherapy or combination therapy, and molecular type.
*
Detailed analysis of industry collaborations, licensing agreements, and financing details driving the market forward.
Learn more about Endometrial Cancer drug opportunities in our comprehensive pipeline report @ Endometrial Cancer Unmet Needs [https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Endometrial Cancer Companies and Competitive Landscape
There are over 50 key companies, including Karyopharm Therapeutics, Eli Lilly, Netris Pharma, Incyte Corporation, and others, developing therapies for Endometrial Cancer, with several candidates now in advanced Phase III and Phase II stages of clinical development.
DelveInsight's Endometrial Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:
*
Subcutaneous
*
Intravenous
*
Oral
*
Intramuscular
Endometrial Cancer products have been categorized under various Molecule types such as:
*
Small molecules
*
Natural metabolites
*
Monoclonal antibodies
Discover the latest advancements in Endometrial Cancer treatment by visiting our website. Stay informed @ Endometrial Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Scope of the Endometrial Cancer Pipeline Report
*
Coverage: Global
*
Endometrial Cancer Companies: Karyopharm Therapeutics, Eli Lilly, Netris Pharma, Incyte Corporation, and others.
*
Endometrial Cancer Therapies: Selinexor, Abemaciclib, NP137, CT-0508, and others.
*
Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination.
*
Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III.
Table of Contents
*
Introduction
*
Executive Summary
*
Endometrial Cancer: Overview
*
Pipeline Therapeutics
*
Therapeutic Assessment
*
Endometrial Cancer - DelveInsight's Analytical Perspective
*
Late Stage Products (Phase III)
*
Mid Stage Products (Phase II)
*
Early Stage Products (Phase I)
*
Preclinical and Discovery Stage Products
*
Inactive Products
*
Endometrial Cancer Key Companies
*
Endometrial Cancer Key Products
*
Endometrial Cancer Unmet Needs
*
Endometrial Cancer Market Drivers and Barriers
*
Endometrial Cancer Future Perspectives and Conclusion
*
Endometrial Cancer Analyst Views
*
Appendix
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=endometrial-cancer-pipeline-grows-as-50-pharma-companies-advance-novel-gynecologic-cancer-therapies-finds-delveinsight-selinexor-abemaciclib-np137-ct0508]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Endometrial Cancer Pipeline Grows as 50+ Pharma Companies Advance Novel Gynecologic Cancer Therapies, Finds DelveInsight | Selinexor, Abemaciclib, NP137, CT-0508 here
News-ID: 4491586 • Views: …
More Releases from ABNewswire
Miami Workplace Retaliation Attorney Anisley Tarragona Outlines Employee Rights …
MIAMI, FL - Workplace retaliation has been the most common type of charge filed with the U.S. Equal Employment Opportunity Commission (EEOC) for seventeen consecutive years, with more than 42,000 charges filed in fiscal year 2024 alone. Miami workplace retaliation attorney Anisley Tarragona of BT Law Group, PLLC (https://btattorneys.com/florida-workplace-retaliation/) explains what qualifies as retaliation, which employee activities are legally protected, and how to recognize early warning signs of unlawful conduct…
California Bankruptcy Attorney Alia Khan Guides Individuals Through the Chapter …
STOCKTON, CA - Filing for Chapter 7 bankruptcy in California follows a structured series of steps under federal law, from credit counseling through a court-ordered discharge that permanently eliminates qualifying debts in as little as three to four months, and understanding each stage can reduce the anxiety many people feel about the process. California bankruptcy attorney Alia Khan of Alia Khan Law (https://akhanlawoffices.com/california-chapter-7-bankruptcy-lawyer/step-by-step-guide/) is walking individuals through each stage of…
New Castle Workers' Compensation Attorneys Lawrence M. Kelly and Joseph A. Georg …
NEW CASTLE, PA - Injured workers in Western Pennsylvania face critical deadlines and complex procedures when seeking workers' compensation benefits, including strict notice requirements that can affect the amount and timing of wage-loss payments. New Castle workers' compensation attorneys Lawrence M. Kelly and Joseph A. George of Luxenberg Garbett Kelly & George P.C. (https://www.lgkg.com/pennsylvania-workers-compensation-lawyer/) explain the benefits available under Pennsylvania law and the steps injured workers must take to protect…
Manhattan Divorce Attorney Juan Luciano Explains How Automatic Orders Protect Pr …
NEW YORK, NY - Disposing of a spouse's belongings during a divorce in New York is prohibited under automatic orders that take effect once a divorce action begins. Manhattan divorce attorney Juan Luciano of Juan Luciano Divorce Lawyer (https://divorcelawfirmnyc.com/can-a-spouse-throw-out-my-belongings-during-a-divorce/) explains how Domestic Relations Law Section 236(B)(2) protects both marital and separate property and what legal remedies are available when a spouse violates these protections.
According to Manhattan divorce attorney Juan Luciano,…
More Releases for Endometrial
Rising Prevalence Of Endometrial Cancer Through Advances In The Endometrial Canc …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Endometrial Cancer Treatment Industry Market Size Be by 2025?
In recent years, the market size for endometrial cancer treatment has experienced consistent growth. It is projected to increase from $31.04 billion in 2024 to $32.09 billion in 2025, indicating a compound annual growth rate (CAGR) of…
Rising Prevalence Of Endometrial Cancer Through Advances In The Endometrial Canc …
The Endometrial Cancer Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Endometrial Cancer Treatment Market Size and Projected Growth Rate?
The Endometrial Cancer Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to…
Endometrial Biopsy Cannulae Market 2023
The report presents detailed information regarding the prominent players and potential competitors in the Endometrial Biopsy Cannulae market. It includes comprehensive insights into their worldwide presence, economic performance, strategies, upcoming product releases, research and development initiatives, and a SWOT analysis. Additionally, the report analyses revenue share and contact details for each player.
This comprehensive report aims to evaluate and forecast the market size for Fuel Monitoring Systems. It analyses revenue, growth…
Hysteroscopic Endometrial Resection Market - Transforming Hysteroscopy, Enhancin …
Newark, New Castle, USA - Growth Plus Reports has published a new report on Hysteroscopic Endometrial Resection Market, which includes a detailed analysis based on competitors and important market segments (2023-2031). The Global Hysteroscopic Endometrial Resection provides a thorough analysis of many segments such as opportunities, market size, developments, innovation, sales, and overall growth of leading players. The research is based on primary and secondary statistical data, and it includes…
Endometrial Ablation Market snapshot 2024
Global Endometrial Ablation Market: Snapshot
With the rising prevalence of gynecology disorders, such as polycystic ovarian disease (PCOD), abnormal vaginal bleeding, the global adoption of endometrial ablation procedures has increased significantly, leading to an impressive rise in the worldwide endometrial ablation market. Apart from this, the upswing in the incidence rate of cervical and endometrial cancer in women is also driving the growth of this market substantially across the world.
Download The…
Global Endometrial Ablation Market: Radiofrequency Endometrial Ablation Devices …
With the presence of large players, such as Hologic Corp., Boston Scientific Corp., Cooper Surgical Inc., Ethicon Inc., and Medtronic Plc at the global level, the worldwide market for endometrial ablation demonstrates a highly competitive landscape, finds a new research report by Transparency Market Research (TMR).
The market players are focusing aggressively on developing their offerings technologically, which is likely to lead to price differentiation, resulting in intense rivalry between these…
